NorthWest Biotherapeutics Inc (NWBO)

[ilovetech]

The 8-K filing from today, January 15, 2026, is a Section 7.01 (Regulation FD Disclosure) that provides the definitive update the market has been waiting for. It essentially formalizes the "Sovereign Shift" we have been tracking.
Forensic Breakdown of the Jan 15 8-K
1. The London Listing Activation (0K95)
The filing confirms that the company has officially applied for the Admission of its Common Stock to the Official List of the Financial Conduct Authority (FCA) and to trading on the London Stock Exchange’s Main Market.
The Ticker: It confirms the use of ticker 0K95.
The Date: Admission is expected to become effective at 8:00 a.m. (London time) on Monday, January 19, 2026—matching the launch of the new POATRs regime.
2. The 75% "Capital Cannon" and Prospectus Exemption
Crucially, the 8-K references the new UK regulatory framework (POATRs). It states that the company intends to utilize the newly expanded 75% issuance threshold for secondary offerings.
The Result: This allows NWBO to issue a significant portion of the 1.06 billion share reserve directly to "certain institutional and strategic investors" in the UK and Europe.
The Shield: By doing this under the POATRs regime, they avoid the traditional U.S. "dark pool" internalization and price-suppression tactics.
3. Sawston Manufacturing "Commercial Readiness"
The filing includes a progress report on the Sawston Facility, stating that the first Grade C manufacturing suite has achieved "operational validation" for commercial production.
The Significance: This moves the asset from "R&D" to "Industrial Capital" on the balance sheet, which is a prerequisite for the Sovereign funding anchors we’ve discussed.